Matica Bio Signs Adenovirus CDMO Contract with North American Medical Research Institution

Supporting the Entire Process from Initial Development to Production

Cha Biotech announced on March 26 that its U.S. subsidiary, Matica Bio, has signed a contract for contract development and manufacturing organization (CDMO) services with a North American medical research institution for an adenovirus-based therapeutic.

Matica Bio exterior. Cha Bio Tech

Under this agreement, Matica Bio will support the entire process for the therapeutic currently under development by the institution, from initial process development to clinical production. This includes establishing research cell lines, process and analytical development, quality testing, creation of a virus bank, and cGMP manufacturing.

The company plans to expand its adenoviral vector production capabilities and strengthen its CDMO business foundation through this contract.

Matica Bio is a subsidiary established in the United States by Cha Biotech to conduct cell and gene therapy (CGT) CDMO business. It operates a manufacturing facility in College Station, Texas.

Based on its analytical and process development capabilities, the company is increasing its contracts in the CGT sector.

This content was produced with the assistance of AI translation services.